No efficient curative option can be currently proposed for refractory metastatic neuroblastomas after completion of conventional treatments. We report a case of successful treatment of a refractory metastatic neuroblastoma after allogeneic bone marrow transplantation (BMT) with reduced-intensity conditioning (RIC) performed for concomitant secondary acute myeloid leukaemia (sAML).
A 10-year-old girl had refractory metastatic, NMYC unamplified, neuroblastoma, despite chemotherapy, surgery, radiotherapy, autologous haematopoietic stem cell transplantation and 13-cis-retinoic acid post-consolidation therapy. After palliative oral VP16 and temozolomide for 12 and 8 months respectively, she developed type II sAML with monosomy 7, concomitant with persistent bone-marrow and blood molecular minimal residual disease (MRD) for neuroblastoma (tyrosine hydroxylase (TH) transcripts) and one bone hot spot on meta-iodobenzaguanidine (MIBG) scan. After leukaemia induction with cytarabine and mitoxantrone, followed by one course of IDA-FLAG, we performed a male, human leucocyte antigen (HLA)-matched, unrelated allogeneic BMT, with RIC based on 2 Gy TBI, but without ATG (Figure 1 ). Engraftment was rapid (neutrophil recovery over 0.5 Â 10 9 /l at day 11, permanent platelets over 30 Â 10 9 /l at day 40), without complications. Post transplant immunosuppression was first based on cyclosporine alone. At day 30, she had full donor lymphocyte chimerism, with stage II acute cutaneous and gastrointestinal graft-versushost disease (GVHD). Blood and bone marrow MRD were negative for both leukaemia (cytogenetic and flow cytometric analysis) and neuroblastoma (TH transcripts), but with a persistent bone MIBG hot spot.
Control of GVHD by immunosuppressive drugs resulted in reappearance of neuroblastoma MRD ( Figure 1 ). Withdrawal of immunosuppressive drugs resulted in new flares of GVHD twice, and remissions of blood neuroblastoma MRD. The second time, the remaining MIBG-scan hot spot had also disappeared ( Figure 2 ). The third time, no GVHD occurred after withdrawal of immunosuppressive treatment. Donor lymphocyte infusion (DLI) containing 5 Â 10 4 CD3 þ /kg and 14 Â 10 4 CD16 þ CD56 þ /kg resulted in an immediate flare of grade II cutaneous GVHD and disappearance of blood and bone marrow neuroblastoma MRD. On day 900 after allogeneic BMT, she was in remission for both leukaemia and neuroblastoma with mild chronic cutaneous GVHD. Treatment had been performed with the child's assent and a written informed consent was obtained from his parents after approval of the protocol by the institutional review board. Here, RIC allogeneic BMT was a curative treatment for two malignancies, normally with a fatal outcome despite conventional treatment. In adults, striking GVT effects after allogeneic BMT have been published with nonmyeloablative or reduced-intensity conditioning, in the treatment of refractory breast and pancreatic cancer, renal cell carcinoma and melanoma. [1] [2] [3] In paediatric cancers, little is known about the possible GVT effect of allogeneic BMT, especially after attenuated conditioning regimens. Here, using an MRD technique with high sensitivity (1 per 10 6
À10
7 cells), 4, 5 we show evidence of the graft-versusneuroblastoma potential of RIC allogeneic BMT. sAML occurring in a patient treated for recurrent cancer also has an extremely bad prognosis. The long-term disappearance of leukaemic cells in our patient cannot be explained solely by the drugs used, 6, 7 and probably relies on the graftversus-leukaemia (GVL) potential of allogeneic BMT. Hence, to our knowledge, it is the first report of simultaneous GVL and graft-versus-tumour after RIC allogeneic BMT, showing clearly the graft-versus-malignancy potential of allogeneic BMT following attenuated regimen.
However, further studies are needed to specify the place of RIC allogeneic BMT in the treatment scheme of refractory neuroblastoma. Figure 2 Evidence of delayed neuroblastoma regression consistent with a GVT effect -sequential images of day 2, anterior MIBG scans of the remaining pelvis bone hot spot 2 weeks before (a) and 3 months (b) and 6 months (c) after RIC allogeneic BMT.
